# Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium

> **NCT06399679** · PHASE2 · RECRUITING · sponsor: **Washington University School of Medicine** · enrollment: 42 (estimated)

## Conditions studied

- Anticholinergic Toxicity

## Interventions

- **DRUG:** Rivastigmine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06399679
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2026-10
- **Final completion:** 2026-11
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06399679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06399679, "Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06399679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*